The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First-in-human, multicenter, dose-escalation, phase I study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma.
J. A. Sosman
Consultant or Advisory Role - Millennium
Honoraria - Millennium
A. A. Adjei
No relevant relationships to disclose
P. LoRusso
Consultant or Advisory Role - Millennium
Research Funding - Millennium
S. A. Michael
No relevant relationships to disclose
G. K. Dy
No relevant relationships to disclose
A. Bowditch
No relevant relationships to disclose
B. Chmielowski
No relevant relationships to disclose
S. Lee
Employment or Leadership Position - Millennium
R. M. Walker
Employment or Leadership Position - Millennium
S. Faucette
Employment or Leadership Position - Millennium
E. S. Izmailova
Employment or Leadership Position - Millennium
V. Bozon
Employment or Leadership Position - Millennium
A. Ribas
Consultant or Advisory Role - Millennium
Honoraria - Millennium